Evolving Risks in Continuous Manufacturing

Dec 10, 2019

Posted by Conner Strong & Buckelew

The continuous manufacturing of pharmaceutical drugs, while still in the early stages of adoption, has the potential to reduce the operating costs of producing drugs by 30%. However, pharmaceutical companies making the switch from batch to continuous processes must also consider the new challenges of reducing risk and securing insurance coverage. Click here to read our white paper and learn more.

For more information on how the adoption of continuous manufacturing will impact insurance coverage and risk management in the pharmaceutical industry, visit our website or contact us




See all Member News